Work

Fluconazole 200 mg Daily As Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Review

Year: 2017

Type: article

Abstract: Introduction: Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients, affecting 3-10% of patients in the first year, with a mortality rate of 30-50%. Fluconazole (FLU) 400 mg daily is the standard of care for prophylaxis based on a survival benefit noted in a previous trial. We present a single-institution retrospective review of prophylaxis with a lower dose of FLU (200 mg daily until day +75) for allogeneic HSCT patients.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2016.12.373